



OPEN

Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease, and Regenerative Medicine

George Adigbli, MBBS, MRCS(Eng),¹ Séverine Ménoret, B.Eng.,² Amy R. Cross, PhD,¹
 Joanna Hester, PhD,¹ Fadi Issa, FRCS(Plast), DPhil,¹ and Ignacio Anegón, MD²

AQ1

Abstract. The humanization of animals is a powerful tool for the exploration of human disease pathogenesis in biomedical research, as well as for the development of therapeutic interventions with enhanced translational potential. Humanized models enable us to overcome biologic differences that exist between humans and other species, while giving us a platform to study human processes in vivo. To become humanized, an immune-deficient recipient is engrafted with cells, tissues, or organoids. The mouse is the most well studied of these hosts, with a variety of immunodeficient strains available for various specific uses. More recently, efforts have turned to the humanization of other animal species such as the rat, which offers some technical and immunologic advantages over mice. These advances, together with ongoing developments in the incorporation of human transgenes and additional mutations in humanized mouse models, have expanded our opportunities to replicate aspects of human allotransplantation and to assist in the development of immunotherapies. In this review, the immune and tissue humanization of various species is presented with an emphasis on their potential for use as models for allotransplantation, graft versus host disease, and regenerative medicine.

(Transplantation XXX;XXX: 00–00).

INTRODUCTION

For decades, studies in immunology have benefited from the ability to experiment on small animal models. However, it is increasingly clear that the mechanistic gap between human and small animal immune responses is significant, leading to challenges in the translation of findings from animal to human that can, on occasion, have devastating results.^{1,2,3} Humanized laboratory animals have been developed to bridge this gap, and provide a powerful method for the preclinical assessment of human immune responses in the context of transplantation and regenerative medicine. The vast majority of these models are created using immunodeficient mice engrafted with

human cells and tissues. Although humanized mice have been extremely useful in the study of many pathologies, the humanization of other species can also be advantageous. The size of other animals, such as rats, pigs, or nonhuman primates, facilitates more challenging surgical procedures, which would be difficult in mice. Additionally, the anatomy and physiology of larger species more closely resembles that of the human. Before the description of gene-specific nucleases (such as meganucleases, zinc finger nucleases [ZFNs], transcription activator-like effector nucleases [TALENs], and CRISPR/Cas9), targeted genome editing was largely restricted to mice, the only species in which robust embryonic stem (ES) cells were available.

AQ2

Received 13 November 2019. Revision received 22 December 2019.

Accepted 7 January 2020.

¹ Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.

AQ4 ² Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, Nantes, France.

This work was supported by generous funding from Biogenouest by Région Pays de la Loire, IBISA program, TEFOR (Investissements d'Avenir French Government program, ANR11-INSB-0014), LabCom SOURIRAT project (ANR-14-LAB5-0008), Labex IGO project (Investissements d'Avenir French Government program, ANR-11-LABX-0016-01), IHU-Cesti project (Investissements d'Avenir French Government program, ANR-10-IBHU-005, Nantes Métropole and Région Pays de la Loire), Fondation Progreffe, the ReSHAPE 825392 EU Horizon 2020, Kidney Research UK, the Academy of Medical Sciences, the Wellcome Trust, and the Clarendon Fund and the Restore Research Trust. F.I. is a Wellcome Trust CRCD Fellow, J.H. is a KRUUK Senior Fellow, and A.R.C. is an Oxford-Celgene Fellow.

The authors declare no conflicts of interest.

I.A. and F.I. planned and wrote the article. F.I. and J.H. performed the included experiments. G.A., S.M., A.R.C., and J.H. wrote and edited the article as well as performing bibliography searches. *G.A., S.M., and A.R.C. contributed equally. F.I. and I.A. are both senior and corresponding authors.

Correspondence: Fadi Issa, FRCS(Plast), DPhil, Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Level 6, John Radcliffe Hospital, Headington, Oxford, UK OX3 9DU. (fadi.issa@nds.ox.ac.uk); Ignacio Anegón, MD, Centre de Recherche en Transplantation et Immunologie, INSERM UMR 1064-CRTI, CHU de Nantes, 30 dv. J. Monnet, 44093, Nantes, France. (ignacio.anegon@univ-nantes.fr).

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 0041-1337/20/XXXXXX-00

DOI: 10.1097/TP.0000000000003177

However, the recent evolution of gene-specific nucleases has allowed the generation of immunodeficient animals in all the above mentioned species. In this review, we aim to explore the qualities and benefits of the available immunodeficient animal models, their potential for reconstitution with human tissues, and how this is benefitting preclinical research in the field of transplantation.

MICE

Immunodeficient Mouse Models

Over the past 2 decades, mice have become the dominant rodent model in biomedical research. The prominence of mice owes largely to the development of methods for genetic manipulation, the subsequent establishment and characterization of murine strains—starting with the first knockout mouse in 1987⁴—and the availability of a wide range of transgenic mice as well as antibodies targeting mouse antigens. Further technological advances targeting mouse gene expression have enabled the experimental reproduction of human allogeneic transplantation within *in vivo* models. For success, such models require: (1) host mice that are rendered genetically immunodeficient, (2) adoptive transfer and engraftment of human immune cells, and (3) transplantation of allogeneic human tissues.

The development of immunodeficient mouse models began following the description of the spontaneously arising severe combined immunodeficiency (*scid*) mutation in C.B-17 mice,⁵ which produced mice lacking effective adaptive immunity. The *scid* mutation affects the *Prkdc* gene for the DNA-dependent protein kinase catalytic subunit, which is critical for DNA repair during V(D)J recombination in T and B cell receptor generation. As a result, SCID mice are incapable of producing mature T and B cells. The experimental replication of this immunodeficiency was first achieved by knocking out the *Rag2* gene, which similarly arrests V(D)J recombination and lymphocyte maturation.⁶ These immunodeficient models therefore permit hematopoietic reconstitution with adoptively transferred human peripheral mononuclear cells⁷ or stem cells,⁸ since effective adaptive antihuman responses can no longer be mounted. It later became clear that human cell reconstitution can be significantly enhanced by targeting mouse innate cells to further limit xenoreactivity. Crossing SCID mice with inbred nonobese diabetic (NOD) mice resulted in mice that not only had defective adaptive immunity but also absent complement C5 (rendering these mice deficient in hemolytic complement) and impaired macrophage and dendritic cell function.^{9,10,11,12,13} In these NOD-*scid* mice, human cell engraftment was up to 10-fold higher than in C.B-17-*scid* mice.¹⁴

Further improvement in human cell engraftment and reconstitution came with the null mutation of the IL-2 receptor common γ -chain,¹⁵ blocking the signaling pathways of IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 and, crucially, diminishing mouse natural killer (NK) cell function through impaired IL-15 signaling. Combining mutations of both adaptive (*scid*, *Rag1/2*) and innate (IL-2R γ) immunity heralded a new wave of severely immunodeficient mice that include NOG (NOD.Cg-*Prkdc*^{*scid*} *Il2rg*^{*tm1Sug*}/JicTac), NSG (NOD.Cg-*Prkdc*^{*scid*} *Il2rg*^{*tm1Wjl*}/SzJ) and BRG (BALB/c *Rag2*^{-/-} *Il2rg*^{*tm1Sug*}/JicTac) mice,¹⁶ expanding opportunities for the successful engraftment of the human

hematopoietic cells. NOG mice and NSG mice differ in the nature of the IL-2 receptor common γ -chain mutation wherein NOG mice lack the cytoplasmic domain whereas NSG mice have a complete null allele. BRG mice differ from NOG/NSG mice being on the Balb/c rather than the NOD background but like NOG mice, they also lack the cytoplasmic tail of the IL-2 receptor common γ -chain. Current evidence suggests that human cells engraft better in NSG/NOG compared with BRG mice.^{17,18} This may be in part due to greater compatibility between human CD47 and NOD SIRP α (discussed below) but perhaps more importantly because the DNA repair defect conferred by the *scid* mutation severely impairs bone marrow stem cell repopulation potential, facilitating exogenous hematopoietic stem cell (HSC) engraftment in a manner not seen in *Rag*-mutant mice.¹⁹ In order to further improve human cell engraftment, later modifications aimed to prevent mouse macrophage-mediated phagocytosis of human hematopoietic cells, which results from impaired “*don't eat me*” signaling via an incompatibility between human CD47 and murine SIRP α . Successful attempts to address this include the transfer of the NOD.*Sirpa* allele, a highly polymorphic variant of SIRP α with high affinity for human CD47,^{20,21} or the human *Sirpa*,^{22,23} to other genetic backgrounds. A summary of all immunodeficient mouse models used for humanized studies is shown in Table 1.

T1

Immune Humanization of Mice: Peripheral Blood Mononuclear Cell (PBMC)-based Models

PBMCs or leukocytes are the most commonly used cell product for humanization in transplant studies, providing a method that is both convenient and cost-effective. Human PBMC mice robustly reconstitute T cells, which have well-established roles in rejection and tolerance. The early identification of donor-specific memory and the rapid rejection of second-set allografts⁴⁵ made adaptive immune cells, especially T cells, the traditional focus of study into pathways of transplant rejection. Indeed, in experimental models, T cells are both necessary and sufficient for the rejection of most allografts.^{46,47} Whereas recreation of these features is important, a caveat of PBMC-humanization is that reconstitution is heavily lymphoid-biased: over 90% of human cells are T cells and the majority express an activated or memory phenotype.⁴⁸ The disproportionately large fraction of the human leukocyte repertoire (usually ~5%–20%) may misrepresent the global immunologic reaction to transplantation, potentially limiting the reliability of experimental findings to the true human alloresponse.

T cell receptor (TCR) recognition of human major histocompatibility complex (MHC) mismatches drives allograft rejection and human graft versus host disease (GvHD). Curiously, MHC molecules display an inherent cross-species immunogenicity. This is beneficial to xenogenic models of GvHD where human CD8⁺ and CD4⁺ T lymphocytes recognize mouse MHC class I and II, respectively, allowing the transferred lymphocytes to simulate systemic proinflammatory responses.²⁴ Moreover, the precursor frequency of human lymphocytes responsive to mouse MHC (0.5% in CD4⁺ cells and 3% in CD8⁺ cells²⁴) is similar to the frequency of alloresponsive lymphocytes (3.9% of CD4⁺ cells and 2.5% of CD8⁺ T cells⁴⁹). Yet, xenogenic models of GvHD can also be confounded by

TABLE 1.**Immunodeficient mouse models**

Name	Strain	Phenotype	Reference
SCID	B6.CB17- <i>Prkdc</i> ^{scid} /SzJ	T and B cell deficiency	5
NOD- <i>scid</i>	NOD.CB17- <i>Prkdc</i> ^{scid} /J	T and B cell deficiency	10
NSG	NOD.Cg- <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Wjl} /SzJ	Phagocytic tolerance T, B, and NK cell deficiency	15
NSG B2M, β2m KO NSG	NOD <i>scid</i> <i>Il2ry</i> ^{null} <i>B2m</i> ^{null}	Phagocytic tolerance T, B, and NK cell deficiency	24
NSG HLA-A2/HDD	NOD.Cg- <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Wjl} Tg (HLA-A2/H2-D/B2M)1Dvs/Sz(NSG-HLA-A2/HHD)	Xeno-GvHD-resistance T, B, and NK cell deficiency	25
NSG HLA-DR	NOG/HLA-DR4/I-Ab ^{-/-}	Human HLA-A2 expression T, B, and NK cell deficiency	26
NSG-SGM3	NOD.Cg- <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Wjl} Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ	Human HLA-DR expression T, B, and NK cell deficiency	27
hIL-6 Tg NSG	NOD.Cg- <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Wjl} Tg(BAC1/2-IL6)	Human IL-3, GM-CSF and SCF expression T, B, and NK cell deficiency	28
NSGW41	NOD.Cg- <i>Kit</i> ^{W-41J} <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Wjl} /WaskJ	Human IL-6 expression T, B, and NK cell deficiency	29
NSGWv/+	NOD/SCID <i>Il2rg</i> ^{-/-} <i>Kit</i> ^{Wv/+}	T, B, and NK cell deficiency, Impaired HSC development	30
NSGWv	NOD/SCID <i>Il2rg</i> ^{-/-} <i>Kit</i> ^{Wv/Wv}	T, B, and NK cell deficiency, Impaired HSC development	30
NBSGW	NOD,B6.SCID <i>Il2ry</i> ^{-/-} <i>Kit</i> ^{W41/W41}	T, B, and NK cell deficiency, Impaired HSC development	31
NOG	NOD.Cg- <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Sug} /JicTac	T, B, and NK cell deficiency Phagocytic tolerance	15
IL-15-NOG Tg	NOD.Cg- <i>Prkdc</i> ^{scid} <i>IL-2Rgc</i> ^{m1Sug} Tg (CMV-IL2/IL15)1-1Jic/JicTac	T, B, and NK cell deficiency Phagocytic tolerance, human IL-15 expression	32
NOG-EXL	NOD.Cg- <i>Prkdc</i> ^{scid} <i>Il2rg</i> ^{tm1Sug} Tg(SV40/HTLV-IL3,CSF2)10-7Jic/JicTac	T, B, and NK cell deficiency Phagocytic tolerance, human GM-CSF & IL-3 expression	33
NOG-IL2 Tg	NOD.Cg- <i>Prkdc</i> ^{scid} <i>IL-2Rgc</i> ^{m1Sug} Tg(CMV-IL2)4-2Jic/JicTac	T, B, and NK cell deficiency Phagocytic tolerance, human IL-2 expression	34
DRAG	NOD.Cg- <i>Rag1</i> ^{tm1Mom} <i>Il2rg</i> ^{tm1Wjl} Tg(HLA-DRA,HLA-DRB1*0401)39-2Kito/ ScasJ	T, B, and NK cell deficiency Phagocytic tolerance, human HLA class II expression	35
NRG	NOD.Cg- <i>Rag1</i> ^{tm1Mom} <i>Il2rg</i> ^{tm1Wjl}	T, B, and NK cell deficiency Phagocytic tolerance	36
SRG	Tg(hSIRPA) <i>Rag2</i> ^{-/-} <i>Il2rg</i> ^{-/-}	T, B, and NK cell deficiency Phagocytic tolerance	22
SRG-W41	NOD, <i>Rag2</i> ^{-/-} <i>Il2rg</i> ^{-/-} <i>Kit</i> ^{Wv/Wv}	T, B, and NK cell deficiency Phagocytic tolerance, Impaired HSC development	37
BALB <i>scid</i>	CBYsmn.CB17- <i>Prkdc</i> ^{scid}	T, B, and NK cell deficiency	38
BRG	BALB/c <i>Rag2</i> ^{-/-} <i>Il2rg</i> ^{tm1Sug} /JicTac	Phagocytic tolerance, Impaired HSC development	20,39
BRG hIL-3 hGM-CSF	BALB/c <i>Rag2</i> ^{-/-} <i>IL-2Rgc</i> ^{-/-} <i>IL3</i> ^h CSF2 ^h	T, B, and NK cell deficiency Human IL-3 & GM-CSF expression	40
BRGS	BALB/c <i>Rag2</i> ^{-/-} <i>IL-2Rgc</i> ^{-/-} NOD. <i>sirpa</i>	T, B, and NK cell deficiency NOD SIRPα expression	20,21
BRGSF	BALB/c <i>Rag2</i> ^{-/-} <i>IL-2Rgc</i> ^{-/-} <i>Flt3</i> ^{-/-}	T, B, and NK cell deficiency, NOD SIRPα expression, impaired HSC development	41
BRgWv	BALB/c <i>Rag2</i> ^{-/-} <i>Il2rg</i> ^{-/-} <i>Kit</i> ^{Wv/Wv}	T, B, and NK cell deficiency, impaired HSC development	30
MISTRG	M-CSF,IL-3,Sirpa, TPO, <i>Rag2</i> ^{-/-} <i>IL-2Rgc</i> ^{-/-}	T, B, and NK cell deficiency, human M-CSF, IL-3, GM-CSF, SIRPα, and TPO expression	42
HUMAMICE	C57BL/6 <i>HLA2</i> ^{+/+} <i>DR1</i> ^{+/+} / <i>H2b2m</i> ^{-/-} <i>IAb</i> ^{-/-} <i>/Rag2</i> ^{-/-} <i>/IL2Rg</i> ^{-/-} <i>/perf</i> ^{-/-}	T, B, and NK cell deficiency No mouse MHC expression, human HLA expression	43
Nude mouse, athymic nude	<i>Foxn1</i> ^{nu}	T and NK cell deficiency	44

HSC, hematopoietic stem cell; MHC, major histocompatibility complex; NK, natural killer; NOD, nonobese diabetic; SCID, severe combined immunodeficiency.

the absence of indirect recognition, abundance of non-human antigens, and the differing distribution of mouse MHC. For example, mice do not constitutively express MHC class II in the vasculature, unlike humans; therefore, humanized GvHD models may underestimate CD4⁺ T cell allorecognition in vascular interactions. However, the

development of GvHD is undesirable in many transplantation studies because it invariably leads to lethal xenogeneic GvHD,^{15,24} an expanding human leukocyte compartment that is not directed at the tissue in question, and a limited experimental window. One strategy to address this has been to produce NSG mice deficient in MHC class I and

II expression.⁵⁰ Intraperitoneal injection of human PBMC in such mice results in the long-term engraftment of functional CD4⁺ and CD8⁺ T cells, which retain the capacity to reject mismatched human islets.⁵⁰

The additional incorporation of non-T cell components in experimental models is desirable for replicating a more complete immune system and human alloresponse. The importance of innate-mediated rejection is of increasing interest.^{51,52} In clinical studies, T cell depletion (eg, with alemtuzumab) has been shown to be insufficient to prevent renal or intestinal allograft rejection. In these studies, rejection was instead associated with monocytic and eosinophilic inflammation, respectively.^{53,54} Experimental cardiac allotransplantation experiments in alymphatic mice results in leukocyte infiltration and proinflammatory cytokine production, highlighting the presence of innate responses that can develop to allografts in the absence of T cells.⁵⁵ Moreover, an array of innate immune cells, such as dendritic cells,⁵⁶ NK,⁵⁷ and mast cells,⁵⁸ have been shown to display immunoregulatory properties important for tolerance induction, and their reconstitution in humanized animals is therefore of interest. Another important consideration is that, as humanized mouse models currently used in transplantation research do not support reconstitution of functional human antigen presenting cells in the recipient host, in vivo assessment of immune alloreactivity is limited to responses triggered by presentation of antigen via the direct pathway. Successful engraftment of functional professional human antigen presenting cells may therefore also ensure that all allorecognition pathways are integrated into the experimental model. To be able to incorporate the entire spectrum of innate and adaptive human immune responses into experimental models of transplantation, support for multilineage human hematopoietic cell reconstitution is key.

An important additional requirement of humanized animal models is engraftment or development of mature human B cells capable of effective antigen presentation and immunoglobulin production. We and others have demonstrated the ability of PBMC-humanized immunodeficient mice to engraft mature human B cells and produce human IgG and IgM (Figure 1A)^{7,59}; however, the frequency of these antibody-producing cells is consistently low and highly variable. However, our experience is that immunodeficient mice humanized with UCB HSCs generate significant numbers of human B cells⁶⁰ (Figure 1B). Despite this, analyses of human B and T cells generated within different HIS mice models have revealed these B cells to be developmentally blocked,⁶¹ with defective peripheral maturation and humoral responses.^{16,62} UCB-humanized mice produce low levels of human IgM and IgG that increases with the development of T lymphocytes; an effect that is enhanced by the introduction of autologous (CD34⁺ CD45⁺) leukocytes (Figure 1C–E). Initially, this was thought to result from an inability of mouse B lymphocyte stimulator (BAFF) to signal human B cells, suggested by the observation that administration of recombinant human BAFF to NOD-*Rag1*^{null}*Prf1*^{null} mice humanized with PBMCs increased B cell engraftment and the ability to mount an antipneumococcal polysaccharide response.⁶³ It has been reported that pre-B and immature B cells differ from mature B cells in not requiring BAFF for their survival.^{64–66} This is supported by a recent study in which expression of

full-length human BAFF from cDNA in the endogenous mouse locus did not improve maturation of human B cells in HIS mice.⁶⁷ An alternative strategy involves the induction of IL-6, which has previously been shown to increase IgG1 expression up to 400-fold.⁶⁸ Knock-in of human IL-6 into HIS BRG mice increases levels of total and antigen-specific human IgG, with a concordant rise in memory and IgG⁺ human B cells, thymocytes, and peripheral T cells,⁶⁹ the latter of which are essential for B cell maturation. Additional strategies being investigated include attempts to improve peripheral lymph node development in humanized mice, which among other benefits can increase CXCL-13 signaling.⁷⁰ This has the potential to induce CD4⁺ cells to become follicular T helper cells during antigen stimulation,^{71,72} in turn providing stimulatory signals to B cells to mediate positive selection of high affinity B cells and differentiation of plasma cells in germinal centers.^{71,73} In transplantation research as in cancer, infection, and autoimmunity, recapitulation of the human B cell response to disease and treatment in humanized animal models will be key in enhancing the accuracy of empirical research outputs that can safely be translated into clinical studies.

Immune Humanization of Mice: Stem Cell-based Models

PBMCs are characterized by a low frequency of self-renewing pluripotent hematopoietic cells and a high proportion of mature lineage-committed cells. Multilineage reconstitution must, therefore, be achieved with the use of HSC-based products rather than PBMCs. Sources of HSCs include human umbilical cord blood,³⁰ adult bone marrow, fetal liver,⁷⁴ and granulocyte colony-stimulating factor-(G-CSF)-mobilized adult PBMCs.⁷⁵

NSG and BRG mice can support long-term multilineage hematopoietic reconstitution following human CD34⁺ HSC transplantation; however, studies have shown that the human T cells that develop are unable to recognize human HLA and mount human-restricted T cell responses because of selection on mouse MHC in the thymus.^{39,76} To overcome this obstacle, it is possible to implant human fetal liver and thymus tissue beneath the kidney capsules of SCID mice to produce “thymic organoids” capable of supporting human T cell development.⁷⁷ To improve systemic reconstitution of T cells and other immune cell types while preserving this principle, the bone marrow-liver-thymus mouse model was created in the more supportive NSG strain, by transplanting human CD34⁺ cells intravenously and implanting human fetal thymus and liver tissue beneath the kidney capsule.^{78,79} Cells developing within this model show functional human-directed immune responses.^{80,81} To reduce the requirement for fetal tissue, a recent model instead utilized neonatal thymus, which has produced human cells capable of rejecting skin xenografts.⁸²

Limitations in HSC humanization include (1) the requirement for myeloablative preconditioning of host mice to create a bone marrow niche in which human HSCs can engraft and (2) the challenges that remain in reconstituting entire the spectrum of immune cells.^{18,83} To overcome these, microenvironmental alterations to favor human hematopoiesis have been described (Figure 2). Methods include (1) mutation of critical murine growth factor receptors, such as the c-kit receptor (NSGW41,




FIGURE 1. Antibody production following BALB/c-Rag2^{-/-}cy^{-/-} mouse transplantation with human PBMC or HSC and a human skin graft. A, BALB/c-Rag2^{-/-}cy^{-/-} mice received a human skin graft followed by 5×10^6 allogeneic PBMC ($n = 9$ mice) or no cells ($n = 3$ mice) 5 wk later. At the point of skin graft rejection (for those receiving PBMC) or long-term survival (>100 days, for those not receiving cells), mice were sacrificed and serum levels of human IgG and human IgM determined by ELISA. All mice receiving 5×10^6 PBMC achieved human leukocyte chimerism levels of $>1\%$ in the spleen. B–E, BALB/c-Rag2^{-/-}cy^{-/-} mice received 4 Gy total body irradiation within 24 h of birth, followed shortly by an intrahepatic injection of 5×10^4 CD34⁺CD45⁻Lin⁻-enriched cells (derived from human UCB by magnetic bead isolation to a purity of over 92%). Six weeks later, mice received a human skin graft from a donor allogeneic to the HSC donor. One group received no further cells ($n = 5$ mice) and another group received an intraperitoneal injection of 5×10^6 mononuclear CD34⁺CD45⁺ cells (MNCs) from the same UCB donor 5 wk postskin transplantation ($n = 4$ mice). Peripheral blood was monitored from 9 wk onwards for the development of (B) live human 7AAD⁻CD45⁺CD19⁺ and (C) 7AAD⁻CD45⁺CD3⁺ leukocytes. Serum from peripheral blood was monitored from 9 wk onwards for the development of human (D) IgG and (E) IgM, measured by specific ELISA. Immunoglobulin was only detectable from week 11 onwards. Data are represented as mean \pm SD. PBMC, peripheral blood mononuclear cell.

NSGWv/+, NSGWv, NBSGW, SRG-W41 and BRGWv mice),^{23,30} (2) inhibition of growth factor receptor function (eg, anti-c-kit receptor antibody),⁸⁴ (3) exogenous human cytokine administration (eg, BlyS for mature human B cell reconstitution⁶⁴ and IL-7 analogues for T cell reconstitution⁷⁶), and (4) knock-in of human cytokine genes, such as in SGM3,²⁷ MISTRG,⁴³ SRG-15,⁸⁵ and hIL-6 Tg NSG²⁸ strains, which include knock-ins of IL-3, IL-15, GM-CSF, M-CSF, or IL-6 to support engraftment of the wider human hematopoietic repertoire, including innate cells and regulatory T cells (Tregs).²⁷

Tissue Transplantation into Humanized Mice

Once the challenge of human immune reconstitution is overcome, the interactions of these immune cells with specific tissues can be assessed. While responses are

simulated by tumor engraftment, alloresponses are simulated by engraftment of human cells or tissues; the most common models being those that engraft human skin,⁸⁶ islets of Langerhans,⁸⁷ or blood vessels.⁸⁸ The most widely used model is that of human skin allotransplantation.⁸⁹⁻⁹³ Skin grafts benefit from tissue accessibility permitting continuous visible monitoring and from an established progression of rejection in skin architecture and leukocyte infiltration. Moreover, skin is easily obtained as discarded tissue, with a single donor being able to provide sufficient tissue for multiple mice, providing a useful internal control. For example, our experience has shown that we are able to transplant skin to up to 50 mice from a single human donor.⁴⁸ Acute and chronic rejection of human solid-organ transplants, such as kidney, heart, or lungs, is characterized by vascular injury.⁹⁴ Rejection of the interposed

Microenvironmental alterations to favour human hematopoiesis




FIGURE 2. Microenvironment alterations to enhance human hematopoiesis. IL, interleukin; SCF, stem cell factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; BlyS, B lymphocyte stimulator.

artery segment in immune humanized mice is a highly relevant model, yet fails to represent the entire vascular tree. Capillaries of human origin are maintained in adult skin grafts on immunodeficient mice, while the graft is simultaneously permeated by mouse capillaries within the first 21 days posttransplantation (Figure 3A–C and Pober et al⁹²). Immune humanization with PBMC selectively destroys human microvasculature, in a process that can be halted by the cotransfer of CD4⁺ Tregs (Figure 3A–E). The humanization of mice with both PBMC and Treg can enable the long-term maintenance of human microvasculature in these skin grafts up to at least 100 days (Figure 3D and E). Some studies use alternate sources of capillaries, such as synthetic microvessels derived from endothelial colony-forming cells in cord blood.^{95–97}

Human organs and tissues demonstrate unique immune functions and immune compartments that would ideally be modeled in homogenous tissues in vivo. This is clearly impractical in rodents, whose small size has traditionally limited the pool of suitable human tissues. Yet studies have ingeniously overcome this obstacle by generating or transferring human muscle, cartilage, bone, liver, kidneys, and intestines. Tissues such as cartilage,⁹⁸ muscle,⁹⁹ and ossicles^{100,101} may be of value in understanding the immunogenicity of vascularized composite allografts. Human satellite cells obtained from skeletal muscles can integrate with NSG mouse muscle to successfully produce muscle fibers and self-renew in situ.⁹⁹ Allogeneic human articular chondrocytes in an agarose scaffold could successfully produce a cartilage matrix in NSG mice reconstituted with CD34⁺ HSC, without signs of antidonor responses.⁹⁸ Recent advances in tissue engineering have

generated protocols for creating 3-dimensional complex organoids from HSC or primary cells. The human bone niche can be reproduced by the subcutaneous differentiation of mesenchymal stromal cells that produce vascularized ossicles, to which human HSCs successfully home and reside.^{100,101} These ossicles have normal bone marrow architecture, a diverse cell repertoire including osteoclasts and osteoblasts, and organized hematopoietic clusters around sinusoids.

Human intestinal organoids have been produced from pluripotent stem cells; true to form, these organoids develop crypt-villus structures and are populated by Paneth and goblet cells.¹⁰² After implantation into the mesentery, organoids grow a vascular pedicle and can be joined to the murine intestine by anastomosis.¹⁰² Engraftment of fetal intestine into the mesentery of SCID mice is also a successful approach generating human intestinal architecture and supporting an enteric nervous system.¹⁰³ Reconstruction of the mouse biliary tree with human extrahepatic cholangiocyte organoids has been demonstrated. Human cholangiocyte organoids grown on scaffolds could be surgically applied to repair and replace the gall bladder wall and common bile ducts.¹⁰⁴ Engraftment of mice with human livers has been achieved by implantation of fetal liver¹⁰⁵ or by the repopulation of immunodeficient mouse livers with human hepatocytes or pluripotent stem cells.¹⁰⁶ Immunodeficient mice are genetically modified to impair hepatic homeostasis, creating space in the hepatic niche and a regenerative stimulus. Urokinase-type plasminogen activator transgenic mice or fumarylacetoacetate hydrolase (Fah) knockouts are common modifications for inducing toxicity in murine liver cells.¹⁰⁷ The transfer of human




FIGURE 3. Human microvessels in human skin allografts are preserved in Treg-treated humanized BALB/c-Rag2^{-/-}cγ^{-/-} mice. BALB/c-Rag2^{-/-}cγ^{-/-} mice received a human skin graft and 5 wk later were injected with 5×10^6 allogeneic PBMCs ($n = 3$ mice) or 5×10^6 allogeneic PBMCs with 5×10^6 ex vivo-expanded CD127^{lo}CD25⁺CD4⁺ human Treg derived from the PBMC donor (ie, autologous Treg, $n = 3$ mice). A further group did not receive any cells (RPMI-1640 medium only, $n = 2$ mice). A, Twenty-one days postadoptive cellular transfer, skin grafts were procured and analyzed by immunohistochemistry for the number of complete cellular rings staining positive for either human CD31 or mouse CD31 within the dermis and epidermis. Complete rings were counted in the entirety of 3 separate sections (ie, in triplicate) per skin sample. Data are represented as mean values of the average of these triplicate values \pm SD from a single in vivo assay using 1 PBMC donor and 1 skin donor, $**P < 0.005$, $****P < 0.0001$, NS, not significant. Representative photomicrographs are shown of human skin sections procured 21 days postadoptive cellular transfer and stained by immunohistochemistry to visualize human CD31⁺ or mouse CD31⁺ cells in (B) mice receiving 5×10^6 PBMCs only and (C) mice receiving 5×10^6 PBMCs with 5×10^6 ex vivo-expanded Treg. Sections are counterstained with hematoxylin. The histology shown is representative of 6 stained sections for each type of stain for each of $n = 3$ mice for each group. Representative photomicrographs are shown of human skin sections from mice receiving PBMCs with Treg, procured >100 days postadoptive cellular transfer and stained by immunohistochemistry for (D) human CD31⁺ cells and (E) mouse CD31⁺ cells. Sections are counterstained with hematoxylin. Multiple complete human and mouse CD31⁺ rings are visible. Photomicrographs are representative of 6 sections from each of $n = 4$ mice. Treg, regulatory T cell; PBMC, peripheral blood mononuclear cell.

hepatocytes has variable engraftment rates, but repopulation of up to 95% has been reported alongside a conserved liver microstructure.¹⁰⁸ The Fah^{-/-}Rag2^{-/-}Il2rg^{-/-} (FRG) mice combined with the NOD strain has been used to engraft both an immune system and repopulate the liver with human hepatocytes, creating dual chimerism and permitting the study of human hepatocyte-immune interactions.¹⁰⁹ As an alternative to models requiring endogenous liver damage, induced pluripotent stem cells (iPS) can produce liver organoids comparable with adult human tissue in gene expression, protein secretion, and drug metabolism.

After implantation into the livers of NSG mice, these organoids integrate with the native tissue and become vascularized within 4 weeks.¹¹⁰

Of interest in modeling renal conditions, complex kidney organoids can be generated from pluripotent stem cells. Kidney organoids successfully contain organized compartments dedicated to nephrons, collecting ducts, stroma, and an endothelial network.¹¹¹ Human kidney organoids can be transplanted into NSG mice, where they join onto the murine vasculature and undergo glomerular and tubular epithelium maturation.¹¹²

Preclinical Models for Immunotherapies

Control of immune responses is a requirement following allotransplantation to ensure graft function and survival. Faithful models of human biology lend themselves to the study of pathogenesis as well as the development of novel therapeutics. In the last 10 years, humanized mouse models have been broadly applied in preclinical studies for the development of the next generation of immunotherapies including costimulation and cytokine modulation, adoptive regulatory cell transfers, chimeric antigen receptor T cells, and nanotechnology for targeted drug delivery.

Immune humanization produces robust models of GvHD. This platform has provided the basis for the efficacy of adoptive CD4⁺ and CD8⁺ Treg therapy,^{90,113,114} mesenchymal stem cell transfers,¹¹⁵ costimulatory blockade such as anti-CD28 or anti-CD3 monoclonal antibodies,^{116,117} blockade of chemokine receptors,¹¹⁸ and small molecule drugs for the inhibition of JAK1/2 signaling.¹¹⁹

The advances in bioengineering human tissues and organs have the potential to enable studies of tissue-specific immune interactions with concurrent assessment of drug metabolism and off-target effects. However, the simultaneous engraftment of immune cells with adult allogeneic skin or vessels is currently the most prevalent model of tissue transplantation. Costimulatory and cytokine modulatory therapies have shown promise in these human tissue transplant models.^{89,120} Nanotechnology was recently applied to humanized models where arteries perfused with nanoparticles carrying silencing RNA could reduce endothelial MHC class II expression and could prevent alloimmune-mediated arteriopathy.¹²¹

Cell therapies rely on humanized models where differences in murine and human biology could have myriad effects on the fate of the transferred cell, different immune subsets, and the allogeneic tissue. The adoptive transfer of polyclonal CD4⁺ and CD8⁺ Tregs has been shown to prevent the rejection of human skin and vessel grafts^{48,86,88,90,122}; these studies have inspired clinical trials into adoptive Treg transfer. Treg transfer therapies have been shown in humanized models to be modulated by their migratory potential,⁸⁶ antigen-specificity,¹²³ and number.⁸⁶ To this end, the development of Treg bestowed with chimeric antigen receptors specific for alloantigens have been implemented in skin graft models to reduce alloimmune injury.^{93,124,125} Importantly, a number of national medical regulatory agencies have now started to acknowledge data from humanized models in submissions for clinical trial approval.

RATS

Immunodeficient Rat Models and Immune Humanization

Rats provide several advantages to mice in experimental studies in transplantation. First, rats are up to 10 times larger than mice, providing an advantage for technically demanding surgical studies. Their size enables the precise implantation of human tumors into relatively small anatomical locations, such as the prostate or specific areas of the brain, as well as enabling the implantation of organoids in orthotopic locations. Size of rats could benefit grafts that require immediate vascularization, such as human fetal vascularized organs, skin, and vessels.

Second, there are no reports of shortened lifespan in rat strains used for generating immunodeficient models. This is unlike most NOD-derived immunodeficient mice, since they show reduced survival due to thymoma beginning at month 8,¹³ although survival may not be reduced for NSG mice.⁷⁵ Third, rats share some immune characteristics with humans that mice do not.¹²⁶ Although some of these are not relevant to immunodeficient models where rat T cells are absent, other characteristics remain pertinent such as macrophage expression of CD4 and/or CD8 or the expression of MHC class II on endothelial cells.¹²⁷ A further advantage of immunodeficient rats is their potential to sustain a larger number of human cells, therefore allowing larger numbers of human immune cells to be procured from the spleen for functional or molecular studies (50–150 × 10⁶ cells compared with 2–10 × 10⁶ cells in mice¹²⁸).

For many years, the only immunodeficient rats were nude rats established from a spontaneous mutation in the *Foxn1* gene¹²⁹ (Table 2). Similar to nude mice, nude rats are only deficient in T cells, while B and NK cell compartments are normal. Furthermore, they have a leaky phenotype whereby older rats produce T cells that develop from a spontaneous rearrangement of their TCRs.^{204,205} Novel immunodeficient rats have been generated with mutations in key genes, including *Rag1*,^{166–168} *Rag2*,^{169–171} and *Il2rg*.¹⁷² *Rag1* and *Rag2* KO rats have normal NK cell generation, and there are residual B and T cells in single *Rag1*, *Rag2*, or *Il2rg* mutants. The severity of immunodeficiency has been increased by combining mutations in the aforementioned genes and/or *Prkdc*.^{167,174,176,177}

Complement levels in most inbred mouse strains,^{9,11} including NOD-derived immunodeficient mice,^{12,13} are undetectable or very low. This led to the recent development of a complement-sufficient NSG strain.²⁰⁶ In contrast, rats have complement levels comparable with humans, as previously shown for several strains,¹¹ including Sprague-Dawley (SD) rats deficient for Rag-1 and Il2rg (SD-RG) and expressing hSIRPα (RRGS).¹²⁸

Rats selectively deficient for B cells and consequently immunoglobulin of all isotypes have been generated by deleting the *Igh6* gene (orthologue of the IgM human gene) using ZFNs¹⁷⁸ or CRISPR/Cas9¹⁷⁹ technologies. Using ZFNs, rats have been generated that lack not only heavy chain immunoglobulins but also both kappa and lambda light chains. These animals were then subsequently humanized by transgenic expression of human immunoglobulin coding sequences allowing the production of fully human monoclonal antibodies of high affinity.^{180,181}

A limitation of humanized allo-GvHD models in immunodeficient mice is the need for total body irradiation to observe clear clinical GvHD, which is increasingly disparate to clinical practice. This irradiation is not required in an immunodeficient rat model in which allo-GvHD was studied.¹²⁸ Additionally, *Prkdc* mutations to obtain a SCID phenotype in many mouse strains (like all NOD-derived immunodeficient strains such as NSG and NOG) increase toxicity due to irradiation in certain models, such as in cancer treatments, since PRKDC is an enzyme essential in DNA repair and its absence generates uncontrolled toxicity in the host tissues. Some^{174,176,182} but not all¹⁷⁷ immunodeficient rats also carry a mutation in the *Prkdc* gene.

TABLE 2.**Transplantation and regenerative medicine models using immunodeficient species other than mice**

Species	Mutated genes	Immune phenotype	Transplantation model	References
Rat	<i>Foxn1</i>	T– (leaky) B+ NK+	Human kidney stem cells, MSCs, neural stem cells, smooth muscle progenitors, retinal cells, pancreatic progenitors, hepatocytes, osteoblasts, astrocytes, oligodendrocytes, stromal stem cells in rotator cuff, bone regeneration, dental follicular cells, cardiomyocytes, intestinal cells	130-165
	<i>Rag1</i>	T– (partially) B– (partially) NK+	Human hepatocytes	166-168
	<i>Rag2</i>	T– (partially) B– (partially) NK+	Human fetal kidneys	169-171
	<i>Il2rg</i>	T– (partially) B– (partially) NK+	Not described	172,173
	<i>Prkdc</i>	T– B– NK+	Human iPS-derived neural precursors	174,175
	<i>Il2rg</i> and <i>Prkdc</i>	T– B– NK–	Human iPS, tumor cells and hepatocytes	174
	<i>Rag1</i> , <i>Rag2</i> and <i>Il2rg</i>	T– B– NK–	Human cancer cells	176
	<i>Rag1</i> and <i>Il2rg</i>	T– B– NK–	Human skin, tumor and hepatocytes	177
	<i>IgM</i>	T+ B– NK+	Rat transplantation models	178,179
	<i>IgM</i> , <i>Igκ</i> , <i>Igλ</i> , hulgls	Human antibodies	Not described	180,181
	<i>Prkdc</i> , <i>Il2rg</i> , <i>hSIRPa</i>	T– B– NK– Mo inhibition	Immune humanization, human cancer cells, iPS	182
	<i>Rag1</i> , <i>Il2rg</i> , <i>hSIRPa</i>	T– B– NK– Mo inhibition	Immune humanization, human GvHD	128
	<i>IL2RG</i>	T– B– NK–	Not described	183
Nonhuman primate Pig	<i>IL2RG</i>	T– B– NK–	Not described	184-186
	<i>RAG1</i> and <i>2</i>	T– B– NK+	Not described	187
	<i>RAG1</i>	T– B– NK+	Not described	188
	<i>RAG2</i>	T– B– NK+	Human iPS	189-191
	<i>RAG2</i> and <i>IL2RG</i>	T– B– NK–	Not described	192
	<i>ARTEMIS</i>	T– B– NK+	Human skin	193,194
Zebra fish	<i>Rag1</i>	T– B– NK+	Human tumors	195
	<i>Rag2</i>	T– B– NK+	Not described	196
	<i>Prkdc</i> and <i>Il2rg</i>	T– B– NK–	Not described	197
	<i>Prkdc</i> and <i>Il2rg</i>	T– B– NK–	Human tumors	198
Rabbit	<i>RAG1</i> and <i>RAG2</i>	T– B– NK+	Human tumors	199
	<i>RAG1</i> , <i>RAG2</i> and <i>IL2RG</i>	T– B– NK–	Not described	200
	<i>FOXN1</i> , <i>RAG1</i> , <i>RAG2</i> , <i>IL2RG</i>	T– B– NK–	Not described	201
	<i>IgH</i>	T+ B– NK+	Not described	202
Syrian hamster	<i>RAG1</i>	T– B– NK+	Not described	203

GvHD, graft versus host disease; NK, natural killer.

As in mice, the molecular incompatibility between rat SIRPα and human CD47 could lead to the elimination of certain types of human cells by macrophages. A recent publication described a rat strain combining mutations in *Prkdc*, *Il2rg*, and the expression of human SIRPα, which allowed better immune humanization compared with animals without human SIRPα.¹⁸² Immune humanization in these animals was performed using CD34⁺ cells from fetal liver alone or in combination with autologous fetal thymus but not with human PBMCs. Despite immune humanization, this report did not describe their use to explore any immune response (such as skin rejection or antihuman tumor responses). Animals from the RRG line, with *Rag1* and *Il2rg* mutations, indefinitely accepted human skin, tumors, and even hepatocytes, but did not

accept human PBMCs.¹⁷⁷ However, RRG animals crossed with rats expressing human SIRPα²⁰⁷ (RRGS animals) or with macrophage depletion allowed immune humanization using human PBMC.¹²⁸ These rats humanized with PBMCs could develop GvHD and reject tumor cells. Furthermore, the presence of normal complement levels in RRGs animals allowed the successful prevention of acute GvHD by using a new depleting antihuman T cell polyclonal antibody. Immune humanization of RRGs animals with cord blood hCD34⁺ cells allowed immune humanization (unpublished). Altogether, these studies indicate that as for mice, immune humanization is more difficult than tissue or tumor humanization and that inhibition of macrophage-mediated phagocytosis of human immune cells by CD47–SIRPα interactions is necessary.

Tissue Humanization of Rats

Nude *Foxn1*^{RNU} rats have been transplanted with a variety of human stem cells or organs in different models of transplantation and regenerative medicine, including models of intestinal transplantation,¹³⁰ bronchus grafts,¹³¹ nephropathy,¹³² liver,^{133,134} cardiac infarct,¹³⁵⁻¹³⁷ bone and chondrocyte healing and regeneration,¹³⁸⁻¹⁴² rotator cuff lesions,^{143,144} tendon lesions,^{145,146} brain or spinal trauma,¹⁴⁷⁻¹⁵⁵ urethral dysfunction,^{156,157} retinal degeneration,¹⁵⁸⁻¹⁶² in vivo differentiation of ES cell-derived pancreatic beta cells,¹⁶³ multiciliated airway cells for the generation of an artificial trachea,¹⁶⁴ and periodontal tissues¹⁶⁵ (Table 2).

The most recently developed models of immunodeficient rats engrafted with solid human tissues are summarized in Table 2. A rat strain, deficient in *Fah* and *Il2rg*, is suitable for the engraftment of human hepatocytes that demonstrate a competitive proliferative advantage in comparison to the resident rat hepatocytes.¹⁷¹ *Rag1*-deficient rats transplanted with human hepatocytes have been able to partially reconstitute the liver.¹⁶⁷ *Il2rg* and *Prkdc* mutated rats have been shown to successfully engraft human iPSCs, tumors, and hepatocytes.¹⁷⁴ *Rag2*-deficient rats have also been transplanted with human fetal kidneys (17–18 weeks gestation) as a method to explore kidney organogenesis in vivo.²⁰⁸ Fetal kidneys increased their size through nephrogenesis and were functionally effective in prolonging the survival of nephrectomized recipients. This is a new animal model for the study of kidney ontogeny and preclinical toxicity of therapeutics agents. In a model of neonatal hypoxic brain injury, *Prkdc*-deficient rats transplanted with human neural precursor cells showed amelioration of lesions.²⁰⁹ It has also been demonstrated that rats from the RRG line bearing *Rag1* and *Il2rg* mutations can indefinitely accept transplanted human skin and tumors.⁹⁴

It is interesting to note that, in some models, immunodeficient rats seem to tolerate xenografts better than immunodeficient mice. This is the case for human pancreatic progenitors that matured faster in rats than mice.¹⁶³ It is possible that accelerated maturation of beta cells was due to similar glucose levels in rats and humans during fasting or after glucose challenge, whereas mice showed high fasting glucose levels and dramatic glucose fluctuations peaking at higher levels after glucose challenge.¹⁶³ Additionally, human tumors grew significantly faster and larger in SD-RG rats than in NSG mice and several fresh lung squamous tumors from patients (PDX model) were successfully implanted in this immunodeficient rat line.¹⁷⁶ The use of immunodeficient rats for the generation of PDX tumors coupled with the humanization of immune responses will likely represent useful models for cancer research.

Rats do, however, have disadvantages when compared with mice. Their larger size implies higher breeding costs. There are also fewer established genetic modifications applicable in rats when compared with immunodeficient mice, such as expression of human cytokines and human MHC or elimination of dendritic cells. In the near future, the application of new genome editing nucleases, such as meganucleases,¹⁶⁶ ZFNs,²¹⁰ TALENs,²¹¹ and CRISPR/Cas9,^{212,213} will facilitate the development of rats with disease-specific mutations including with Cre-conditional mutations.^{214,215}

IMMUNODEFICIENCY AND HUMANIZATION IN OTHER SPECIES

Pigs are an attractive species for the experimental implantation of human cells or tissues, due to their large size and physiological proximity to humans. Several lines of immunodeficient pigs carrying spontaneous or induced inactivation of *RAG1*, *RAG2*, *ARTEMIS*, or *IL2RG* alone or combined (*RAG2* and *IL2RG*) have been described.²¹⁶ However, in pigs that carry mutations of the *IL2RG*,¹⁸⁴⁻¹⁸⁶ *RAG1*,¹⁸⁸ *RAG2*,¹⁹¹ *RAG2*, and *IL2RG*¹⁹² genes, there are no descriptions of transplantation of human cells or tissues. In T⁽⁻⁾B⁽⁻⁾NK⁽⁺⁾ SCID pigs carrying spontaneous point mutations in the *ARTEMIS* gene,¹⁹³ human cryopreserved deceased skin was accepted for at least 28 days.¹⁹⁴ Since the successful in utero engraftment and differentiation of human CD34⁺ progenitors in immunocompetent pigs has been reported,²¹⁷ it has been proposed that immunodeficient pigs could be used in this setting to generate large numbers of human cells.²¹⁶ Human lymphocytes can recognize porcine MHC molecules and respond at similar levels to human allogeneic MHC proteins.^{218,219} The homology between human and porcine MHC molecules means that antibodies against HLA class II antigens have a propensity to also bind swine leukocyte antigen class II antigens. In the context of future immune humanization of immunodeficient pigs, it is important to point out that porcine SIRPα binds to human CD47 and thus provides inhibition of pig macrophage phagocytosis of human leukocytes.²²⁰

Zebrafish offer the attractive characteristic of optical transparency and ease of breeding. Although immunodeficient zebrafish have been described, such as those deficient for *Rag2*,¹⁹⁶ *Rag1*,¹⁹⁵ or for both *Prkdc* and *Il2rg*,¹⁹⁸ they have only been used for implanting human tumors and not for normal human tissue or cell transplantation. Human CD34⁺ HSCs have been transplanted into immunocompetent zebrafish where they home to the caudal niche and engage endothelial cells and undergo cell division.²²¹

Rabbits have excellent fecundity and a convenient size for many experimental procedures, while remaining small enough for maintenance as a laboratory animal. Immunocompromised rabbits have been produced with deficiencies in *RAG1* and *RAG2*¹⁹⁹; *RAG1*, *RAG2*, and *IL2RG*²⁰⁰ *FOXN1*, *RAG1*, *RAG2*, *IL2RG*,²⁰¹ and *IgH*,²⁰² but to date they have only been used for implantation of human tumor cells. Similarly, Syrian hamsters are small animal models used in several areas of research.²²² Syrian hamsters deficient for *RAG1* have been described but have not yet been humanized.²⁰³ Finally in nonhuman primates, immunocompromised marmosets mutated for *IL2RG* using ZFNs and TALENs have been described,¹⁸³ but there have been no reports on immune humanization or transplantation of human tissues in these animals.

CONCLUSIONS

It is clear that the use of humanized animals is important in providing opportunities to understand the mechanisms of human immune responses to tissue transplants in vivo. These models provide an excellent path for the development and assessment of human-based immunotherapies in a human context. Regulatory agencies are starting to accept data from humanized models as indicative of

therapeutic efficacy of a human-specific agent. A number of newer models have been developed to provide a more complete picture of human immune responses or to allow surgical procedures that would otherwise be impossible in mice. For most studies, is not necessarily the case that the most advanced model should be used, rather that a specific model should be selected that answers the experimental question at hand. It is also important to note the significant limitations that exist. First, none of the models described fully reproduce all elements of a functional human immune system in the peripheral blood, and also in tissues as for macrophages and innate lymphoid cells.²²³ Second, human immune responses result from a complex interaction of cells between the peripheral, tissue, and lymphoid systems. Many of these elements do not exist even in the most advanced models. Third, these models do not yet provide a complete substitute for pharmacokinetic studies in larger animal models. However, it is arguable that some safety elements related to the effects on human leukocytes (eg, a cytokine storm) would be observed in a fully humanized animal. Nevertheless, agents that are found to be unsuccessful in a humanized animal are unlikely to be successful after translation, providing a method for filtering out therapies that would fail in expensive and risky early clinical trials.

PERSPECTIVES

In cancer studies, the outcomes of therapeutic adoptive T cell transfers could be modeled in immune-humanized mice engrafted with patient tumor (PDX models) and the therapeutic cell transfer.²²⁴ Patient material could also be used in generating relevant and insightful humanized models for transplantation. An example is a recent study that engrafted mice with pericardiophrenic artery segments obtained from the donor and PBMC from the recipient. Interestingly, histological changes in the artery were associated with development of chronic lung allograft dysfunction in the patient, indicating the presence of alloreactive T cells at time of transplant.²²⁵ Such models could provide a method for developing customized patient-specific therapies.

The importance of the microbiota in immune education is recognized, but the role of the microbiome in tolerance and rejection is an ongoing subject of research.²²⁶ Allotransplantation and immunosuppression are associated with changes in gut microbiota population frequency and diversity.²²⁷ Allogenic animal models have shown the ability of commensal bacteria in the gut or on the skin to influence allograft survival.²²⁸⁻²³⁰ In NSG mice reconstituted by neonatal administration of human CD34⁺ cells, antibiotics modified skin allograft tolerance and the success of the immunotherapy teplizumab.¹¹⁷ The impact of microbiota on allograft survival and sensitivity to immunointervention is a problem for the reproducibility of animal work, wherein animals housed in different facilities vary significantly in their microbiome composition.^{231,232} Indeed, mice from different animal houses have different capacities to tolerate or reject orthotopic lung allografts and the same principle applies to the tolerance of xenografts in immune humanized animals.²³¹ Methods do exist to partially engraft human microbiota into mature murine intestinal environments, but the mammalian microbiome is

species-specific and symbiotic.²³³⁻²³⁵ Not all human intestinal flora is maintained in a mouse intestine after transfer, resulting in bacterial diversity that is not representative of the original donor.

Rats have some characteristics that make them attractive for humanization. Their larger size makes them well suited for orthotopic implantation of human organoids of different tissues differentiated from human iPS or ES cells. New and exciting models are emerging using interspecies chimeras to generate organs from a different species in an animal knockout for a tissue master gene. For these models, the rat is often used.^{236,237} Nevertheless, species chimerism decreases with time during the embryo development and this could be due to in embryo immune responses, including SIRP α -CD47 incompatibilities that could benefit from the use of SIRP α humanized rats. Additionally, a number of rat knockout models that reproduce human genetic diseases better than mice, such as in dystrophin²³⁸ or *Aire*-deficient²³⁹ rats, could be used in an immunodeficient-humanized setting.

In nonmouse immunodeficient models, the rat is the only species that has been immune humanized. Yet very little has yet been performed in terms of tissue transplantation outside of current mouse models. It is likely that immune humanized pigs will be developed in the future. Given the recent advances in genetic modification, the tools now exist to produce immunodeficient animals in a range of species. The demand for immunodeficient recipients will likely increase in the future for the implantation of cells derived from human iPS and ES cells, such as hepatocytes, pancreatic beta cells, and retinal cells. Recent years have seen an explosion in the production of genetically humanized transgenic mice to sustain specific and functional components of human cells and tissues, which may move across species. Regenerative medicine is directly contributing to the pool of human tissues and organs that can be incorporated into other species, having already produced kidney organoids, muscle, cartilage, bone, intestines, bladder walls, and liver. The next step will be to apply these models to the study of cell, tissue, and solid organ transplantation and rejection. For example, antibody-mediated rejection could be modeled in transgenic mice with functional B cell antibody responses combined with a vascular transplant, or tissue-specific immunogenicity could be assessed using kidney organoid implantation together with T cell engraftment. The next generation of immunotherapies, such as cellular therapies and immunosuppressant-loaded nanoparticles, will require human immunity and tissues to thoroughly assess their functionality, immunogenicity, and target specificity. The development of advanced humanized animals with greater likeness to functional multilineage human immune systems will therefore permit the study and replication of more complex responses in allotransplantation, GvHD, and regenerative medicine.

REFERENCES

1. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. *Lancet*. 2006;368:1387-1391.
2. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. *N Engl J Med*. 2006;355:1018-1028.
3. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J Immunol*. 2004;172:2731-2738.

4. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. *Cell*. 1987;51:503–512.
5. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. *Nature*. 1983;301:527–530.
6. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. *Cell*. 1992;68:855–867.
7. Mosier DE, Gulizia RJ, Baird SM, et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency. *Nature*. 1988;335:256–259.
8. Lapidot T, Pflumio F, Doedens M, et al. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. *Science*. 1992;255:1137–1141.
9. Wetsel RA, Fleischer DT, Haviland DL. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. *J Biol Chem*. 1990;265:2435–2440.
10. Serreze DV, Leiter EH. Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. *J Immunol*. 1988;140:3801–3807.
11. Ong GL, Mattes MJ. Mouse strains with typical mammalian levels of complement activity. *J Immunol Methods*. 1989;125:147–158.
12. Baxter AG, Cooke A. Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. *Diabetes*. 1993;42:1574–1578.
13. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/ltsz-scid mice. *J Immunol*. 1995;154:180–191.
14. Greiner DL, Shultz LD, Yates J, et al. Improved engraftment of human spleen cells in NOD/ltsz-scid/scid mice as compared with C.B-17-scid/scid mice. *Am J Pathol*. 1995;146:888–902.
15. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gammaC>null mouse: an excellent recipient mouse model for engraftment of human cells. *Blood*. 2002;100:3175–3182.
16. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. *Nat Rev Immunol*. 2007;7:118–130.
17. Pearson T, Shultz LD, Miller D, et al. Non-obese diabetic-recombination activating gene-1 (NOD-rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2R gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment. *Clin Exp Immunol*. 2008;154:270–284.
18. Brehm MA, Cuthbert A, Yang C, et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2RGAMMA>null mutation. *Clin Immunol*. 2010;135:84–98.
19. Qing Y, Lin Y, Gerson SL. An intrinsic BM hematopoietic niche occupancy defect of HSC in scid mice facilitates exogenous HSC engraftment. *Blood*. 2012;119:1768–1771.
20. Legrand N, Huntington ND, Nagasawa M, et al. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. *Proc Natl Acad Sci U S A*. 2011;108:13224–13229.
21. Yamauchi T, Takenaka K, Urata S, et al. Polymorphic sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. *Blood*. 2013;121:1316–1325.
22. Strowig T, Rongvaux A, Rathinam C, et al. Transgenic expression of human signal regulatory protein alpha in rag2-/-gammaC-/- mice improves engraftment of human hematopoietic cells in humanized mice. *Proc Natl Acad Sci U S A*. 2011;108:13218–13223.
23. Labarthe L, Henriquez S, Lambotte O, et al. Frontline science: exhaustion and senescence marker profiles on human T cells in BRGFS-A2 humanized mice resemble those in human samples. *J Leukoc Biol*. 2020;107:27–42.
24. SNELL GD. Methods for the study of histocompatibility genes. *J Genet*. 1948;49:87–108.
25. Rosenberg AS, Mizuochi T, Singer A. Analysis of T-cell subsets in rejection of kb mutant skin allografts differing at class I MHC. *Nature*. 1986;322:829–831.
26. Tilney NL, Strom TB, Kupiec-Weglinski JW. Humoral and cellular mechanisms in acute allograft injury. *J Pediatr*. 1987;111(Pt 2):1000–1003.
27. Issa F, Hester J, Goto R, et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. *Transplantation*. 2010;90:1321–1327.
28. King MA, Covassin L, Brehm MA, et al. Human peripheral blood leukocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. *Clin Exp Immunol*. 2009;157:104–118.
29. Macedo C, Orkis EA, Popescu I, et al. Contribution of naïve and memory T-cell populations to the human alloimmune response. *Am J Transplant*. 2009;9:2057–2066.
30. Brehm MA, Kenney LL, Wiles MV, et al. Lack of acute xenogeneic graft-versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. *Faseb J*. 2019;33:3137–3151.
31. Liu W, Li XC. An overview on non-T cell pathways in transplant rejection and tolerance. *Curr Opin Organ Transplant*. 2010;15:422–426.
32. LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. *J Immunol*. 2007;178:7503–7509.
33. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). *Transplantation*. 2003;76:120–129.
34. Wu T, Bond G, Martin D, et al. Histopathologic characteristics of human intestine allograft acute rejection in patients pretreated with thymoglobulin or alemtuzumab. *Am J Gastroenterol*. 2006;101:1617–1624.
35. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. *Transplantation*. 2002;73:853–861.
36. Morelli AE, Thomson AV. Tolerogenic dendritic cells and the quest for transplant tolerance. *Nat Rev Immunol*. 2007;7:610–621.
37. Gill RG. NK cells: elusive participants in transplantation immunity and tolerance. *Curr Opin Immunol*. 2010;22:649–654.
38. de Vries VC, Noelle RJ. Mast cell mediators in tolerance. *Curr Opin Immunol*. 2010;22:643–648.
39. Mosier DE, Gulizia RJ, Baird SM, et al. Human immunodeficiency virus infection of human-PBL-SCID mice. *Science*. 1991;251:791–794.
40. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. *Curr Opin Endocrinol Diabetes Obes*. 2010;17:120–125.
41. Watanabe Y, Takahashi T, Okajima A, et al. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac>null (NOG) mice (hu-HSC NOG mice). *Int Immunol*. 2009;21:843–858.
42. Lang J, Ota T, Kelly M, et al. Receptor editing and genetic variability in human autoreactive B cells. *J Exp Med*. 2016;213:93–108.
43. Schmidt MR, Appel MC, Giassi LJ, et al. Human blys facilitates engraftment of human PBL derived B cells in immunodeficient mice. *PLoS One*. 2008;3:e3192.
44. Mackay F, Schneider P. Cracking the BAFF code. *Nat Rev Immunol*. 2009;9:491–502.
45. Trembl JF, Hao Y, Stadanlick JE, et al. The blys family: toward a molecular understanding of B cell homeostasis. *Cell Biochem Biophys*. 2009;53:1–16.
46. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. *Cytokine Growth Factor Rev*. 2008;19:263–276.
47. Lang J, Zhang B, Kelly M, et al. Replacing mouse BAFF with human BAFF does not improve B-cell maturation in hematopoietic humanized mice. *Blood Adv*. 2017;1:2729–2741.
48. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. *Proc Natl Acad Sci U S A*. 1989;86:7547–7551.
49. Yu H, Borst C, Schickel JN, et al. A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. *Blood*. 2017;129:959–969.
50. Bar-Ephraim YE, Mebius RE. Innate lymphoid cells in secondary lymphoid organs. *Immunol Rev*. 2016;271:185–199.
51. Crotty S. T follicular helper cell differentiation, function, and roles in disease. *Immunity*. 2014;41:529–542.
52. Ueno H, Banachereau J, Vinuesa CG. Pathophysiology of T follicular helper cells in humans and mice. *Nat Immunol*. 2015;16:142–152.
53. Sage PT, Sharpe AH. T follicular regulatory cells. *Immunol Rev*. 2016;271:246–259.
54. Cosgun KN, Rahmigh S, Mende N, et al. Kit regulates HSC engraftment across the human-mouse species barrier. *Cell Stem Cell*. 2014;15:227–238.
55. Holyoake TL, Nicolini FE, Eaves CJ. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. *Exp Hematol*. 1999;27:1418–1427.
56. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/ltsz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. *J Immunol*. 2005;174:6477–6489.

57. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. *Science*. 2004;304:104–107.
58. Chicha L, Tussiwand R, Traggiai E, et al. Human adaptive immune system $\text{rag2}^{-/-}$ - $\gamma\text{ma}\mu^{-/-}$ mice. *Ann N Y Acad Sci*. 2005;1044:236–243.
59. McCune JM, Namikawa R, Kaneshima H, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. *Science*. 1988;241:1632–1639.
60. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. *Nat Med*. 2006;12:1316–1322.
61. Lan P, Tonomura N, Shimizu A, et al. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. *Blood*. 2006;108:487–492.
62. Wege AK, Melkus MW, Denton PW, et al. Functional and phenotypic characterization of the humanized BLT mouse model. *Curr Top Microbiol Immunol*. 2008;324:149–165.
63. Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. *J Virol*. 2009;83:7305–7321.
64. Brown ME, Zhou Y, McIntosh BE, et al. A humanized mouse model generated using surplus neonatal tissue. *Stem Cell Reports*. 2018;10:1175–1183.
65. McDermott SP, Eppert K, Lechman ER, et al. Comparison of human cord blood engraftment between immunocompromised mouse strains. *Blood*. 2010;116:193–200.
66. Gonzalez L, Strbo N, Podack ER. Humanized mice: novel model for studying mechanisms of human immune-based therapies. *Immunol Res*. 2013;57:326–334.
67. Billerbeck E, Barry WT, Mu K, et al. Development of human CD4+foxp3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Ry(null) humanized mice. *Blood*. 2011;117:3076–3086.
68. Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. *Nat Biotechnol*. 2014;32:364–372.
69. Herndler-Brandstetter D, Shan L, Yao Y, et al. Humanized mouse model supports development, function, and tissue residency of human natural killer cells. *Proc Natl Acad Sci U S A*. 2017;114:E9626–E9634.
70. Ono R, Watanabe T, Kawakami E, et al. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model. *Ebiomedicine*. 2019;41:584–596.
71. Issa F, Hester J, Milward K, et al. Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model. *PLoS One*. 2012;7:e53331.
72. Wu DC, Hester J, Nadig SN, et al. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. *Transplantation*. 2013;96:707–716.
73. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. *Nat Med*. 2010;16:809–813.
74. Zaitzu M, Issa F, Hester J, et al. Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses. *JCI Insight*. 2017;2:89381.
75. Bézie S, Meistermann D, Boucault L, et al. Ex vivo expanded human non-cytotoxic CD8+CD45RCLW/-Tregs efficiently delay skin graft rejection and GVHD in humanized mice. *Front Immunol*. 2017;8:2014.
76. Dawson NA, Lamarche C, Hoeppli RE, et al. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. *JCI Insight*. 2019;4:123672.
77. Pober JS, Bothwell AL, Lorber MI, et al. Immunopathology of human T cell responses to skin, artery and endothelial cell grafts in the human peripheral blood lymphocyte/severe combined immunodeficient mouse. *Springer Semin Immunopathol*. 2003;25:167–180.
78. Boardman DA, Philippeos C, Fruhwirth GO, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. *Am J Transplant*. 2017;17:931–943.
79. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. *Am J Transplant*. 2018;18:293–307.
80. Shepherd BR, Enis DR, Wang F, et al. Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells. *Faseb J*. 2006;20:1739–1741.
81. Abrahami P, Qin L, Chang WG, et al. Blocking MHC class II on human endothelium mitigates acute rejection. *JCI Insight*. 2016;1:e85293.
82. Merola J, Reschke M, Pierce RW, et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. *JCI Insight*. 2019;4:129739.
83. Perrier-Groult E, Pérès E, Pasdeloup M, et al. Evaluation of the biocompatibility and stability of allogeneic tissue-engineered cartilage in humanized mice. *PLoS One*. 2019;14:e0217183.
84. Garcia SM, Tamaki S, Lee S, et al. High-yield purification, preservation, and serial transplantation of human satellite cells. *Stem Cell Reports*. 2018;10:1160–1174.
85. Holzapfel BM, Hutmacher DW, Nowlan B, et al. Tissue engineered humanized bone supports human hematopoiesis in vivo. *Biomaterials*. 2015;61:103–114.
86. Reinisch A, Hernandez DC, Schallmoser K, et al. Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice. *Nat Protoc*. 2017;12:2169–2188.
87. Cortez AR, Poling HM, Brown NE, et al. Transplantation of human intestinal organoids into the mouse mesentery: a more physiologic and anatomic engraftment site. *Surgery*. 2018;164:643–650.
88. Nagy N, Marsiano N, Bruckner RS, et al. Xenotransplantation of human intestine into mouse abdomen or subcutaneous tissue: novel platforms for the study of the human enteric nervous system. *Neurogastroenterol Motil*. 2018;30:e13212.
89. Sampaziotis F, Justin AW, Tysoe OC, et al. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. *Nat Med*. 2017;23:954–963.
90. Irudayaswamy A, Muthiah M, Zhou L, et al. Long-term fate of human fetal liver progenitor cells transplanted in injured mouse livers. *Stem Cells*. 2018;36:103–113.
91. Yuan L, Liu X, Zhang L, et al. A chimeric humanized mouse model by engrafting the human induced pluripotent stem cell-derived hepatocyte-like cell for the chronic hepatitis B virus infection. *Front Microbiol*. 2018;9:908.
92. Naritomi Y, Sanoh S, Ohta S. Utility of chimeric mice with humanized liver for predicting human pharmacokinetics in drug discovery: comparison with in vitro-in vivo extrapolation and allometric scaling. *Biol Pharm Bull*. 2019;42:327–336.
93. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in $\text{fah}^{-/-}$ - $\text{rag2}^{-/-}$ - $\text{il2rg}^{-/-}$ mice. *Nat Biotechnol*. 2007;25:903–910.
94. Wilson EM, Bial J, Tarlow B, et al. Extensive double humanization of both liver and hematopoiesis in FRGN mice. *Stem Cell Res*. 2014;13(Pt A):404–412.
95. Ng SS, Saeb-Parsy K, Blackford SJI, et al. Human ips derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold. *Biomaterials*. 2018;182:299–311.
96. Takasato M, Er PX, Chiu HS, et al. Generation of kidney organoids from human pluripotent stem cells. *Nat Protoc*. 2016;11:1681–1692.
97. van den Berg CW, Ritsma L, Avramut MC, et al. Renal subcapsular transplantation of PSC-derived kidney organoids induces neovascularogenesis and significant glomerular and tubular maturation in vivo. *Stem Cell Reports*. 2018;10:751–765.
98. Hannon M, Lechanteur C, Lucas S, et al. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. *Transfusion*. 2014;54:353–363.
99. Zheng J, Liu Y, Liu Y, et al. Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. *Sci Transl Med*. 2013;5:168ra9.
100. Tobin LM, Healy ME, English K, et al. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. *Clin Exp Immunol*. 2013;172:333–348.
101. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent fab' antibody. *Am J Transplant*. 2012;12:2630–2640.
102. Gulden E, Vudattu NK, Deng S, et al. Microbiota control immune regulation in humanized mice. *JCI Insight*. 2017;2:91709.
103. Burger DR, Parker Y, Guinta K, et al. PRO 140 monoclonal antibody to CCR5 prevents acute xenogeneic graft-versus-host disease in NOD-scid IL-2rynull mice. *Biol Blood Marrow Transplant*. 2018;24:260–266.

104. Betts BC, Bastian D, Iamsawat S, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. *Proc Natl Acad Sci U S A*. 2018;115:1582–1587.
105. de Leur K, Luk F, van den Bosch TPP, et al. The effects of an IL-21 receptor antagonist on the alloimmune response in a humanized mouse skin transplant model. *Transplantation*. 2019;103:2065–2074.
106. Cui J, Qin L, Zhang J, et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. *Nat Commun*. 2017;8:191.
107. Issa F, Milward K, Goto R, et al. Transiently activated human regulatory T cells upregulate BCL-XL expression and acquire a functional advantage in vivo. *Front Immunol*. 2019;10:889.
108. Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. *Sci Transl Med*. 2011;3:83ra42.
109. MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. *J Clin Invest*. 2016;126:1413–1424.
110. Boroughs AC, Larson RC, Choi BD, et al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. *JCI Insight*. 2019;5:126194.
111. Wildner G. Are rats more human than mice? *Immunobiology*. 2019;224:172–176.
112. Ladhoff J, Fleischer B, Hara Y, et al. Immune privilege of endothelial cells differentiated from endothelial progenitor cells. *Cardiovasc Res*. 2010;88:121–129.
113. Ménoret S, Ouisse LH, Tesson L, et al. In vivo analysis of human immune responses in immunodeficient rats. *Transplantation*. 2019. In press.
114. Festing MF, May D, Connors TA, et al. An athymic nude mutation in the rat. *Nature*. 1978;274:365–366.
115. Colston MJ, Fieldsteel AH, Dawson PJ. Growth and regression of human tumor cell lines in congenitally athymic (rnu/rnu) rats. *J Natl Cancer Inst*. 1981;66:843–848.
116. Vaessen LM, Broekhuizen R, Rozing J, et al. T-cell development during ageing in congenitally athymic (nude) rats. *Scand J Immunol*. 1986;24:223–235.
117. Ménoret S, Fontanière S, Jantz D, et al. Generation of rag1-knockout immunodeficient rats and mice using engineered meganucleases. *Faseb J*. 2013;27:703–711.
118. Tsuchida T, Zheng YW, Zhang RR, et al. The development of humanized liver with rag1 knockout rats. *Transplant Proc*. 2014;46:1191–1193.
119. Zschemisch NH, Glage S, Wedekind D, et al. Zinc-finger nuclease mediated disruption of rag1 in the LEW/ztm rat. *BMC Immunol*. 2012;13:60.
120. Noto FK, Adjan-Steffey V, Tong M, et al. Sprague dawley rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. *Mol Cancer Ther*. 2018;17:2481–2489.
121. Liu Q, Zhou S, Fan C, et al. Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging. *Sci Rep*. 2017;7:3597.
122. Kuijk EW, Rasmussen S, Blokzijl F, et al. Generation and characterization of rat liver stem cell lines and their engraftment in a rat model of liver failure. *Sci Rep*. 2016;6:22154.
123. Mashimo T, Takizawa A, Voigt B, et al. Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. *PLoS One*. 2010;5:e8870.
124. Mashimo T, Takizawa A, Kobayashi J, et al. Generation and characterization of severe combined immunodeficiency rats. *Cell Rep*. 2012;2:685–694.
125. He D, Zhang J, Wu W, et al. A novel immunodeficient rat model supports human lung cancer xenografts. *Faseb J*. 2019;33:140–150.
126. Ménoret S, Ouisse LH, Tesson L, et al. Generation of immunodeficient rats with rag1 and il2rg gene deletions and human tissue grafting models. *Transplantation*. 2018;102:1271–1278.
127. Verma MK, Clemens J, Burzenski L, et al. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. *J Immunol Methods*. 2017;446:47–53.
128. Ménoret S, Iscache AL, Tesson L, et al. Characterization of immunoglobulin heavy chain knockout rats. *Eur J Immunol*. 2010;40:2932–2941.
129. Panzer SE, Wilson NA, Verhoven BM, et al. Complete B cell deficiency reduces allograft inflammation and intragraft macrophages in a rat kidney transplant model. *Transplantation*. 2018;102:396–405.
130. Osborn MJ, Ma B, Avis S, et al. High-affinity igg antibodies develop naturally in ig-knockout rats carrying germine human igh/igk/igl loci bearing the rat CH region. *J Immunol*. 2013;190:1481–1490.
131. Ouisse LH, Gautreau-Rolland L, Devilder MC, et al. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. *BMC Biotechnol*. 2017;17:3.
132. Yang X, Zhou J, He J, et al. An immune system-modified rat model for human stem cell transplantation research. *Stem Cell Reports*. 2018;11:514–521.
133. Jung CJ, Ménoret S, Brussels L, et al. Comparative analysis of piggybac, CRISPR/cas9 and TALEN mediated BAC transgenesis in the zygote for the generation of humanized SIRPA rats. *Sci Rep*. 2016;6:31455.
134. Kitano K, Schwartz DM, Zhou H, et al. Bioengineering of functional human induced pluripotent stem cell-derived intestinal grafts. *Nat Commun*. 2017;8:765.
135. Guhaire J, Itagaki R, Stubbendorff M, et al. Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder. *Transpl Int*. 2016;29:1337–1348.
136. Santeramo I, Herrera Perez Z, Illera A, et al. Human kidney-derived cells ameliorate acute kidney injury without engrafting into renal tissue. *Stem Cells Transl Med*. 2017;6:1373–1384.
137. Igarashi Y, Tateno C, Tanaka Y, et al. Engraftment of human hepatocytes in the livers of rats bearing bone marrow reconstructed with immunodeficient mouse bone marrow cells. *Xenotransplantation*. 2008;15:235–245.
138. Pettinato G, Ramanathan R, Fisher RA, et al. Scalable differentiation of human ipscs in a multicellular spheroid-based 3D culture into hepatocyte-like cells through direct wnt/ β -catenin pathway inhibition. *Sci Rep*. 2016;6:32888.
139. Sougawa N, Miyagawa S, Fukushima S, et al. Laminin-511 supplementation enhances stem cell localization with suppression in the decline of cardiac function in acute infarct rats. *Transplantation*. 2019;103:e119–e127.
140. Saucourt C, Vogt S, Merlin A, et al. Design and validation of an automated process for the expansion of peripheral blood-derived CD34+ cells for clinical use after myocardial infarction. *Stem Cells Transl Med*. 2019;8:822–832.
141. Zhao X, Chen H, Xiao D, et al. Comparison of non-human primate versus human induced pluripotent stem cell-derived cardiomyocytes for treatment of myocardial infarction. *Stem Cell Reports*. 2018;10:422–435.
142. Pytlík R, Rentsch C, Soukup T, et al. Efficacy and safety of human mesenchymal stromal cells in healing of critical-size bone defects in immunodeficient rats. *Physiol Res*. 2017;66:113–123.
143. Saito A, Ooki A, Nakamura T, et al. Targeted reversion of induced pluripotent stem cells from patients with human cleidocranial dysplasia improves bone regeneration in a rat calvarial bone defect model. *Stem Cell Res Ther*. 2018;9:12.
144. Mahmoud EE, Kamei N, Shimizu R, et al. Therapeutic potential of multilineage-differentiating stress-enduring cells for osteochondral repair in a rat model. *Stem Cells Int*. 2017;2017:8154569.
145. Wang T, Nimkingratana P, Smith CA, et al. Enhanced chondrogenesis from human embryonic stem cells. *Stem Cell Res*. 2019;39:101497.
146. Takahashi K, Ogura N, Tomoki R, et al. Applicability of human dental follicle cells to bone regeneration without dexamethasone: an in vivo pilot study. *Int J Oral Maxillofac Surg*. 2015;44:664–669.
147. Harada Y, Mifune Y, Inui A, et al. Rotator cuff repair using cell sheets derived from human rotator cuff in a rat model. *J Orthop Res*. 2017;35:289–296.
148. Gumucio JP, Flood MD, Roche SM, et al. Stromal vascular stem cell treatment decreases muscle fibrosis following chronic rotator cuff tear. *Int Orthop*. 2016;40:759–764.
149. Kremen TJ, Bez M, Sheyn D, et al. In vivo imaging of exogenous progenitor cells in tendon regeneration via superparamagnetic iron oxide particles. *Am J Sports Med*. 2019;47:2737–2744.
150. Nakano N, Matsumoto T, Takayama K, et al. Age-dependent healing potential of anterior cruciate ligament remnant-derived cells. *Am J Sports Med*. 2015;43:700–708.
151. Lu P, Woodruff G, Wang Y, et al. Long-distance axonal growth from human induced pluripotent stem cells after spinal cord injury. *Neuron*. 2014;83:789–796.

152. Bohaciakova D, Hruska-Plochan M, Tsunemoto R, et al. A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors. *Stem Cell Res Ther*. 2019;10:83.
153. Beretta S, Cunningham KM, Haus DL, et al. Effects of human ES-derived neural stem cell transplantation and kindling in a rat model of traumatic brain injury. *Cell Transplant*. 2017;26:1247–1261.
154. Lien BV, Tuszyński MH, Lu P. Astrocytes migrate from human neural stem cell grafts and functionally integrate into the injured rat spinal cord. *Exp Neurol*. 2019;314:46–57.
155. Nori S, Khazaei M, Ahuja CS, et al. Human oligodendrocytic neural progenitor cells delivered with chondroitinase ABC facilitate functional repair of chronic spinal cord injury. *Stem Cell Reports*. 2018;11:1433–1448.
156. Nagoshi N, Khazaei M, Ahlfors JE, et al. Human spinal oligodendrocytic neural progenitor cells promote functional recovery after spinal cord injury by axonal remyelination and tissue sparing. *Stem Cells Transl Med*. 2018;7:806–818.
157. Munter JP, Beugels J, Munter S, et al. Standardized human bone marrow-derived stem cells infusion improves survival and recovery in a rat model of spinal cord injury. *J Neurol Sci*. 2019;402:16–29.
158. Haus DL, López-Velázquez L, Gold EM, et al. Transplantation of human neural stem cells restores cognition in an immunodeficient rodent model of traumatic brain injury. *Exp Neurol*. 2016;281:1–16.
159. Yokobori S, Sasaki K, Kanaya T, et al. Feasibility of human neural stem cell transplantation for the treatment of acute subdural hematoma in a rat model: a pilot study. *Front Neurol*. 2019;10:82.
160. Li Y, Green M, Wen Y, et al. Efficacy and safety of immuno-magnetically sorted smooth muscle progenitor cells derived from human-induced pluripotent stem cells for restoring urethral sphincter function. *Stem Cells Transl Med*. 2017;6:1158–1167.
161. Nakajima N, Tamaki T, Hirata M, et al. Purified human skeletal muscle-derived stem cells enhance the repair and regeneration in the damaged urethra. *Transplantation*. 2017;101:2312–2320.
162. McLelland BT, Lin B, Mathur A, et al. Transplanted hesc-derived retina organoid sheets differentiate, integrate, and improve visual function in retinal degenerate rats. *Invest Ophthalmol Vis Sci*. 2018;59:2586–2603.
163. Tu HY, Watanabe T, Shirai H, et al. Medium- to long-term survival and functional examination of human ipsc-derived retinas in rat and primate models of retinal degeneration. *Ebiomedicine*. 2019;39:562–574.
164. Seiler MJ, Aramant RB, Jones MK, et al. A new immunodeficient pigmented retinal degenerate rat strain to study transplantation of human cells without immunosuppression. *Graefes Arch Clin Exp Ophthalmol*. 2014;252:1079–1092.
165. Seiler MJ, Lin RE, McLelland BT, et al. Vision recovery and connectivity by fetal retinal sheet transplantation in an immunodeficient retinal degenerate rat model. *Invest Ophthalmol Vis Sci*. 2017;58:614–630.
166. Thomas BB, Zhu D, Lin TC, et al. A new immunodeficient retinal dystrophic rat model for transplantation studies using human-derived cells. *Graefes Arch Clin Exp Ophthalmol*. 2018;256:2113–2125.
167. Bruin JE, Asadi A, Fox JK, et al. Accelerated maturation of human stem cell-derived pancreatic progenitor cells into insulin-secreting cells in immunodeficient rats relative to mice. *Stem Cell Reports*. 2015;5:1081–1096.
168. Okuyama H, Ohnishi H, Nakamura R, et al. Transplantation of multiciliated airway cells derived from human ips cells using an artificial tracheal patch into rat trachea. *J Tissue Eng Regen Med*. 2019;13:1019–1030.
169. Kaku M, Kitami M, Rosales Rocabado JM, et al. Recruitment of bone marrow-derived cells to the periodontal ligament via the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 axis. *J Periodontol Res*. 2017;52:686–694.
170. Chang NK, Gu J, Gu S, et al. Arterial flow regulator enables transplantation and growth of human fetal kidneys in rats. *Am J Transplant*. 2015;15:1692–1700.
171. Beldick SR, Hong J, Altamentova S, et al. Severe-combined immunodeficient rats can be used to generate a model of perinatal hypoxic-ischemic brain injury to facilitate studies of engrafted human neural stem cells. *PLoS One*. 2018;13:e0208105.
172. Geurts AM, Cost GJ, Rémy S, et al. Generation of gene-specific mutated rats using zinc-finger nucleases. *Methods Mol Biol*. 2010;597:211–225.
173. Shultz LD, Saito Y, Najima Y, et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2R gamma(null) humanized mice. *Proc Natl Acad Sci U S A*. 2010;107:13022–13027.
174. Suzuki M, Takahashi T, Katano I, et al. Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/shi-scid/ycnull mouse. *Int Immunol*. 2012;24:243–252.
175. Rahmig S, Kronstein-Wiedemann R, Fohgrub J, et al. Improved human erythropoiesis and platelet formation in humanized NSGW41 mice. *Stem Cell Reports*. 2016;7:591–601.
176. McIntosh BE, Brown ME, Duffin BM, et al. Nonirradiated NOD.B6.SCID il2ry/- kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells. *Stem Cell Reports*. 2015;4:171–180.
177. Katano I, Nishime C, Ito R, et al. Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. *Sci Rep*. 2017;7:17230.
178. Ito R, Takahashi T, Katano I, et al. Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. *J Immunol*. 2013;191:2890–2899.
179. Katano I, Takahashi T, Ito R, et al. Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse. *J Immunol*. 2015;194:3513–3525.
180. Danner R, Chaudhari SN, Rosenberger J, et al. Expression of HLA class II molecules in humanized NOD.rag1ko.IL2RGCKO mice is critical for development and function of human T and B cells. *PLoS One*. 2011;6:e19826.
181. Harris DT, Badowski M, Balamurugan A, et al. Long-term human immune system reconstitution in non-obese diabetic (NOD)-rag (-)-gamma chain (-) (NRG) mice is similar but not identical to the original stem cell donor. *Clin Exp Immunol*. 2013;174:402–413.
182. Miller PH, Rabu G, MacAldaz M, et al. Analysis of parameters that affect human hematopoietic cell outputs in mutant c-kit-immunodeficient mice. *Exp Hematol*. 2017;48:41–49.
183. Rich BS, Honeyman JN, Darcy DG, et al. Endogenous antibodies for tumor detection. *Sci Rep*. 2014;4:5088.
184. Willinger T, Rongvaux A, Takizawa H, et al. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. *Proc Natl Acad Sci U S A*. 2011;108:2390–2395.
185. Li Y, Mention JJ, Court N, et al. A novel flt3-deficient HIS mouse model with selective enhancement of human DC development. *Eur J Immunol*. 2016;46:1291–1299.
186. Zeng Y, Liu B, Rubio MT, et al. Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells. *PLoS One*. 2017;12:e0173754.
187. Pantelouris EM. Absence of thymus in a mouse mutant. *Nature*. 1968;217:370–371.
188. Samata B, Kikuchi T, Miyawaki Y, et al. X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation. *J Neurosci Methods*. 2015;243:68–77.
189. Ma Y, Shen B, Zhang X, et al. Heritable multiplex genetic engineering in rats using CRISPR/cas9. *PLoS One*. 2014;9:e89413.
190. Sato K, Oiwa R, Kumita W, et al. Generation of a nonhuman primate model of severe combined immunodeficiency using highly efficient genome editing. *Cell Stem Cell*. 2016;19:127–138.
191. Suzuki S, Iwamoto M, Saito Y, et al. Il2rg gene-targeted severe combined immunodeficiency pigs. *Cell Stem Cell*. 2012;10:753–758.
192. Watanabe M, Nakano K, Matsunari H, et al. Generation of interleukin-2 receptor gamma gene knockout pigs from somatic cells genetically modified by zinc finger nuclease-encoding mra. *PLoS One*. 2013;8:e76478.
193. Kang JT, Cho B, Ryu J, et al. Biallelic modification of IL2RG leads to severe combined immunodeficiency in pigs. *Reprod Biol Endocrinol*. 2016;14:74.
194. Huang J, Guo X, Fan N, et al. RAG1/2 knockout pigs with severe combined immunodeficiency. *J Immunol*. 2014;193:1496–1503.
195. Ito T, Sendai Y, Yamazaki S, et al. Generation of recombination activating gene-1-deficient neonatal piglets: a model of T and B cell deficient severe combined immune deficiency. *PLoS One*. 2014;9:e113833.
196. Lee K, Kwon DN, Ezashi T, et al. Engraftment of human ips cells and allogeneic porcine cells into pigs with inactivated RAG2 and accompanying severe combined immunodeficiency. *Proc Natl Acad Sci U S A*. 2014;111:7260–7265.
197. Choi YJ, Kim E, Reza AMMT, et al. Recombination activating gene-2null severe combined immunodeficient pigs and mice engraft human induced pluripotent stem cells differently. *Oncotarget*. 2017;8:69398–69407.

198. Suzuki S, Iwamoto M, Hashimoto M, et al. Generation and characterization of RAG2 knockout pigs as animal model for severe combined immunodeficiency. *Vet Immunol Immunopathol.* 2016;178:37–49.
199. Lei S, Ryu J, Wen K, et al. Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency. *Sci Rep.* 2016;6:25222.
200. Waide EH, Dekkers JC, Ross JW, et al. Not all SCID pigs are created equally: two independent mutations in the artemis gene cause SCID in pigs. *J Immunol.* 2015;195:3171–3179.
201. Singer AJ, Tuggle C, Ahrens A, et al. Survival of human cadaver skin on severe combined immune deficiency pigs: proof of concept. *Wound Repair Regen.* 2019;27:426–430.
202. Tokunaga Y, Shirouzu M, Sugahara R, et al. Comprehensive validation of T- and B-cell deficiency in rag1-null zebrafish: implication for the robust innate defense mechanisms of teleosts. *Sci Rep.* 2017;7:7536.
203. Tang Q, Abdelfattah NS, Blackburn JS, et al. Optimized cell transplantation using adult rag2 mutant zebrafish. *Nat Methods.* 2014;11:821–824.
204. Tang Q, Iyer S, Lobbardi R, et al. Dissecting hematopoietic and renal cell heterogeneity in adult zebrafish at single-cell resolution using RNA sequencing. *J Exp Med.* 2017;214:2875–2887.
205. Yan C, Brunson DC, Tang Q, et al. Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish. *Cell.* 2019;177:1903–1914.e14.
206. Song J, Zhong J, Guo X, et al. Generation of RAG 1- and 2-deficient rabbits by embryo microinjection of TALENs. *Cell Res.* 2013;23:1059–1062.
207. Yang D, Xu J, Zhu T, et al. Effective gene targeting in rabbits using RNA-guided cas9 nucleases. *J Mol Cell Biol.* 2014;6:97–99.
208. Song J, Yang D, Ruan J, et al. Production of immunodeficient rabbits by multiplex embryo transfer and multiplex gene targeting. *Sci Rep.* 2017;7:12202.
209. Flisikowska T, Thorey IS, Offner S, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. *PLoS One.* 2011;6:e21045.
210. Miao J, Ying B, Li R, et al. Characterization of an N-terminal non-core domain of RAG1 gene disrupted Syrian hamster model generated by CRISPR Cas9. *Viruses.* 2018;10:E243.
211. Tesson L, Usal C, Ménoret S, et al. Knockout rats generated by embryo microinjection of TALENs. *Nat Biotechnol.* 2011;29:695–696.
212. Ménoret S, De Cian A, Tesson L, et al. Homology-directed repair in rodent zygotes using cas9 and TALEN engineered proteins. *Sci Rep.* 2015;5:14410.
213. Li D, Qiu Z, Shao Y, et al. Heritable gene targeting in the mouse and rat using a CRISPR-cas system. *Nat Biotechnol.* 2013;31:681–683.
214. Ma Y, Yu L, Pan S, et al. CRISPR/cas9-mediated targeting of the rosa26 locus produces cre reporter rat strains for monitoring cre-loxp-mediated lineage tracing. *FEBS J.* 2017;284:3262–3277.
215. Meek S, Mashimo T, Burdon T. From engineering to editing the rat genome. *Mamm Genome.* 2017;28:302–314.
216. Boettcher AN, Loving CL, Cunnick JE, et al. Development of severe combined immunodeficient (SCID) pig models for translational cancer modeling: future insights on how humanized SCID pigs can improve preclinical cancer research. *Front Oncol.* 2018;8:559.
217. Fujiki Y, Fukawa K, Kameyama K, et al. Successful multilineage engraftment of human cord blood cells in pigs after in utero transplantation. *Transplantation.* 2003;75:916–922.
218. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. *J Immunol.* 1995;155:5249–5256.
219. Hundrieser J, Hein R, Pokoyski C, et al. Role of human and porcine MHC DRB1 alleles in determining the intensity of individual human anti-pig T-cell responses. *Xenotransplantation.* 2019;26:e12523.
220. Boettcher AN, Cunnick JE, Powell EJ, et al. Porcine signal regulatory protein alpha binds to human CD47 to inhibit phagocytosis: implications for human hematopoietic stem cell transplantation into severe combined immunodeficient pigs. *Xenotransplantation.* 2019;26:e12466.
221. Hamilton N, Sabroe I, Renshaw SA. A method for transplantation of human hscs into zebrafish, to replace humanised murine transplantation models. *F1000Res.* 2018;7:594.
222. Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, et al. Syrian hamster as an animal model for the study of human influenza virus infection. *J Virol.* 2018;92:e01693–e01700.
223. Alisjahbana A, Mohammad I, Gao Y, et al. Human macrophages and innate lymphoid cells: tissue-resident innate immunity in humanized mice. *Biochem Pharmacol.* 2019;113672. [Epub ahead of print]
224. Jespersen H, Lindberg MF, Donia M, et al. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. *Nat Commun.* 2017;8:707.
225. Siemieni T, Knöfel AK, Ius F, et al. Transplant arteriosclerosis in humanized mice reflects chronic lung allograft dysfunction and is controlled by regulatory T cells. *J Thorac Cardiovasc Surg.* 2019;157:2528–2537.
226. Sepulveda M, Pirozzolo I, Alegre ML. Impact of the microbiota on solid organ transplant rejection. *Curr Opin Organ Transplant.* 2019;24:679–686.
227. Xiao J, Peng Z, Liao Y, et al. Organ transplantation and gut microbiota: current reviews and future challenges. *Am J Transl Res.* 2018;10:3330–3344.
228. Lei YM, Chen L, Wang Y, et al. The composition of the microbiota modulates allograft rejection. *J Clin Invest.* 2016;126:2736–2744.
229. Lei YM, Sepulveda M, Chen L, et al. Skin-restricted commensal colonization accelerates skin graft rejection. *JCI Insight.* 2019;4:e127569.
230. Rey K, Manku S, Enns W, et al. Disruption of the gut microbiota with antibiotics exacerbates acute vascular rejection. *Transplantation.* 2018;102:1085–1095.
231. Guo Y, Wang Q, Li D, et al. Vendor-specific microbiome controls both acute and chronic murine lung allograft rejection by altering CD4+ foxp3+ regulatory T cell levels. *Am J Transplant.* 2019;19:2705–2718.
232. McIntosh CM, Chen L, Shaiber A, et al. Gut microbes contribute to variation in solid organ transplant outcomes in mice. *Microbiome.* 2018;6:96.
233. Staley C, Kaiser T, Beura LK, et al. Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. *Microbiome.* 2017;5:87.
234. Wrzosek L, Ciocan D, Borentain P, et al. Transplantation of human microbiota into conventional mice durably reshapes the gut microbiota. *Sci Rep.* 2018;8:6854.
235. Arrieta MC, Walter J, Finlay BB. Human microbiota-associated mice: a model with challenges. *Cell Host Microbe.* 2016;19:575–578.
236. Hirabayashi M, Goto T, Hoshi S. Pluripotent stem cell-derived organogenesis in the rat model system. *Transgenic Res.* 2019;28:287–297.
237. Masaki H, Nakauchi H. Interspecies chimeras for human stem cell research. *Development.* 2017;144:2544–2547.
238. Larcher T, Lafoux A, Tesson L, et al. Characterization of dystrophin deficient rats: a new model for duchenne muscular dystrophy. *PLoS One.* 2014;9:e110371.
239. Ossart J, Moreau A, Autrusseau E, et al. Breakdown of immune tolerance in AIRE-deficient rats induces a severe autoimmune poly-endocrinopathy-candidiasis-ectodermal dystrophy-like autoimmune disease. *J Immunol.* 2018;201:874–887.

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

AQ1—For indexing purposes, please confirm that author names have been correctly identified as given names (blue) and surnames (red). Color in the byline will not appear on the final published version.

AQ2—Please note that duplicate references have been deleted and the references have been renumbered both in text and list for sequential ordering.

AQ3—Please confirm if the edits made to the sentence "Immunocompromised rabbits have..." are fine.

AQ4—Please provide department or division details for affiliation 2.